Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftriaxone + sulbactam + edta
- Development stage
- Phase 3
- Lead developer
- Venus Remedies
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Ceftriaxone + sulbactam + EDTA (commonly abbreviated as CSE) is a fixed-dose combination of three agents designed to combat multidrug-resistant (MDR) gram-negative bacterial infections. Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis. Sulbactam acts as a beta-lactamase inhibitor, protecting ceftriaxone from degradation by extended-spectrum beta-lactamases (ESBLs). EDTA (ethylenediaminetetraacetic acid), an antibiotic resistance breaker and non-antibiotic adjuvant, chelates divalent metal ions such as zinc and calcium that are essential for the activity of metallo-beta-lactamases (MBLs) and efflux pumps in bacteria. This triple combination extends the spectrum of activity to include ESBL- and MBL-producing bacteria, disrupts biofilms, increases membrane permeability, reduces efflux pump function, and inhibits curli formation. The drug has been approved by the Drug Controller General of India for treatment of complicated urinary tract infections caused by MDR pathogens[1][3][4][5][6]. It has undergone Phase 3 clinical trials for this indication.
- Brand names
- EloresCefbact ES
- Other names
- ceftriaxone–sulbactam–edtaceftriaxone+sulbactam+disodium edtacse
02
Targets
Bacterial biofilm extracellular polymeric substance matrix componentsβ-lactamaseNeuraminidaseBacterial Efflux PumpPBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on ceftriaxone + sulbactam + edta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftriaxone + sulbactam + edta.